HCG (human chorionic gonadotropin)

What it is

Human chorionic gonadotropin (hCG) is a glycoprotein hormone, structurally related to luteinizing hormone (LH), used off-label and on-label in men to stimulate testicular testosterone production and support sperm production — most commonly as an add-on to testosterone replacement therapy (TRT) in men who want to preserve fertility, or on its own in men with hypogonadotropic hypogonadism.¹ Unlike testosterone, hCG works "upstream," stimulating the testes directly rather than replacing the hormone the testes would otherwise make, which is why it doesn't shut down sperm production the way TRT alone does.

Also known as: Pregnyl and Novarel (urinary-derived, powder for reconstitution) and Ovidrel (recombinant, prefilled syringe, marketed mainly for ovulation induction and IVF).¹ It's naturally produced during pregnancy by the placenta — pharmaceutical hCG is either purified from human urine or manufactured recombinantly.

hCG is FDA-approved as a biologic, but for a different set of indications than its TRT-adjunct use: ovulation induction in women, an assist in fertility treatments, prepubertal cryptorchidism (undescended testicles) not caused by an anatomical blockage, and select cases of hypogonadotropic hypogonadism in men. Using it to preserve fertility during testosterone therapy is a common, guideline-referenced practice, but it remains technically off-label.¹

How it works

hCG binds and activates the LH/hCG receptor, a receptor expressed on testicular Leydig cells. Because hCG and LH are structurally related — both built on the same protein scaffold, differing mainly in their hormone-specific subunit — hCG effectively functions as a longer-acting stand-in for LH.¹

Once hCG binds that receptor, it triggers a signaling cascade inside the Leydig cell that raises intracellular cAMP and activates the enzymes needed to convert cholesterol into testosterone. The result is a rise in intratesticular testosterone — concentrations roughly 100 times higher than what circulates in blood, and the level of local androgen exposure that's needed to support sperm production within the testes. Exogenous testosterone, by contrast, can't replicate this local effect because it suppresses rather than stimulates the testes' own activity. That's mechanistically why hCG, given alongside TRT or on its own in men with intact testicular function but insufficient LH, can maintain or restore sperm production where testosterone alone cannot.

hCG has a considerably longer half-life than the body's own LH — commonly cited around 24–36 hours, versus LH's minutes-scale pulsatile secretion — which is what allows for infrequent dosing (every other day to a few times weekly) rather than constant stimulation. It's given by subcutaneous or intramuscular injection; there's no oral form, since a protein hormone like hCG would simply be broken down by digestive enzymes.¹

What the research shows

Animal / preclinical evidence

hCG's receptor pharmacology at the Leydig cell has long been established through basic endocrine physiology research, which underlies its mechanistic rationale. The research brief for this compound doesn't identify dedicated modern animal-model efficacy trials beyond this foundational physiology — the available clinical literature focuses on human case series and cohorts, which are summarized below.

Human evidence

The most cited fertility-preservation evidence comes from a retrospective case series of 49 men with testosterone-related azoospermia or severe low sperm counts, treated with hCG (3,000 IU subcutaneously every other day), often combined with other agents.² Spermatogenesis returned or improved in 47 of 49 men (95.9%), with an average time to recovery of 4.6 months. It's an encouraging result, but it's retrospective, has no control group, and mixed in other therapies alongside hCG — so it can't cleanly isolate hCG's individual contribution.

A smaller retrospective cohort of 25 men used weekly hCG monotherapy (not combined with testosterone) for hypogonadal symptoms.³ The majority reported improved erectile function (86%) and libido (80%), with no significant changes in hematocrit, blood sugar, or PSA and no clotting events — but average serum testosterone didn't rise significantly at the dose studied, suggesting the dose used may have been too low to reliably normalize testosterone even though symptoms improved.

A 2025 systematic review and meta-analysis pooling 10 randomized trials found that combining a SERM (like enclomiphene) with hCG produced significantly higher testosterone than hCG alone, hinting that hCG monotherapy may be less potent for testosterone restoration than combination regimens.⁵ Separately, a 2023 access study surveying compounding pharmacies found that 61.5% of outsourcing pharmacies that previously compounded hCG stopped doing so after the 2020 biologic reclassification, with three-quarters citing that regulatory change directly as the reason — a stark illustration of how the drug's real-world availability, not just its clinical evidence, has shifted.⁴

Honest bottom line: hCG's role in maintaining or restoring fertility during and after testosterone therapy is mechanistically sound and consistently supported across the (admittedly small) studies available, even though no large randomized trial has confirmed it. Its ability to normalize testosterone levels as a standalone therapy is less well established, and there's no long-term cardiovascular or oncologic safety dataset comparable to what exists for testosterone itself.

Typical use and dosing

Published fertility-preservation and combination regimens most often used 3,000 IU subcutaneously every other day, sometimes alongside clomiphene, tamoxifen, anastrozole, or recombinant FSH depending on clinical response.² The hCG-monotherapy cohort studying hypogonadal symptoms used a lower, once-weekly dose.³ Clinical practice literature describing hCG as an adjunct to ongoing TRT commonly cites roughly 500–1,500 IU subcutaneously two to three times per week, though the ideal balance between fertility preservation, cost, and injection burden hasn't been established in large trials.

There's no FDA-approved dosing regimen specific to TRT-adjunct or fertility-preservation use, since that application remains off-label; duration is typically tied to how long concurrent TRT continues, or run as a defined course to reverse testosterone-induced suppression after stopping testosterone.

Safety, side effects, and who should avoid it

Reported side effects in the available (small) studies are generally mild: injection-site discomfort, occasional headache, and — less commonly — gynecomastia, mood changes, nausea, and acne related to hCG's downstream androgenic effect through increased testosterone and estradiol.¹ Notably, unlike testosterone, hCG has not been shown to reliably raise hematocrit in the small studies available, though this is based on limited data rather than a large safety database.

Thromboembolic events have occasionally been reported with hCG use in some contexts, though the small monotherapy cohort reviewed here observed none. Older, animal-derived chorionic gonadotropin products carried a higher allergic-reaction profile; those products were withdrawn decades ago, and modern human urinary and recombinant hCG have a different, generally better-tolerated profile. There are no major, well-characterized drug-drug interactions in the literature — combining hCG with exogenous testosterone is a deliberate, common strategy for fertility preservation, not an interaction of concern.

Monitoring typically includes baseline and periodic testosterone, LH, FSH, and estradiol to track response; semen analysis at baseline and periodically if fertility preservation or restoration is the goal; and hematocrit and PSA monitoring consistent with standard testosterone-therapy-adjacent practice, given hCG's downstream androgenic effect.¹

Regulatory status

hCG is FDA-approved as a biologic for ovulation induction, as an assisted-reproduction adjunct, for prepubertal cryptorchidism, and for select male hypogonadotropic hypogonadism — but not specifically for maintaining fertility during testosterone therapy, which remains off-label, even though it's explicitly recommended in that context by the American Urological Association's testosterone deficiency guideline.¹⁰ It is not a DEA-scheduled controlled substance.¹

The single most important recent regulatory event for hCG happened on March 23, 2020: under the Biologics Price Competition and Innovation Act, hCG (along with FSH, LH, and a few related hormones) was reclassified from an approved drug to a licensed biologic product, making it ineligible for standard 503A/503B pharmacy compounding.⁶ Compounding hCG now requires a costly Biologics License Application that most outsourcing pharmacies have chosen not to pursue, and the Alliance for Pharmacy Compounding formally petitioned the FDA in 2021 to reconsider the change, arguing it was legally inconsistent with the agency's own prior guidance.⁷⁸ As of this writing, hCG remains classified as a biologic, and most patients now access it through FDA-approved branded or generic products (Pregnyl, Novarel, Ovidrel) rather than compounded formulations — a shift that has increased cost and reduced formulation flexibility.

Frequently asked questions